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Background.Arterialhypertensioninrenaltransplantrecipients(RTR)isassociatedwithincreasedmorbidmortality.Inthegeneral
population, home blood pressure monitoring (HBPM) was found to be superior to oﬃce blood pressure (OBP) in identifying true
hypertensive patients. The aim of this study was to investigate HBPM for the assessment of blood pressure proﬁle in RTR. Metho-
dology and Principal Findings. We included prospectively 87 stable RTR. Sitting OBP was measured during the outpatient clinic.
HBPM was performed by measuring BP every morning and night for 4 days. The accepted limits for the OBP and HBPM, were
respectively, 140/90mmHg and 135/85mmHg. Patients were classiﬁed as “normotensive,” “uncontrolled,” “white-coat hyperten-
sive” and “masked hypertensive”, (OBP below the limit and HBPM above). During the study, 81 patients (55 males, age 48.5 ± 14
years) were available for analysis. The mean OBP and HBP were 138/83±14/10mmHg and 133/79±14/8mmHg; 29% of patients
were uncontrolled, 28% normotensive, 21% white coat, and 21% masked hypertensive. Age, glycemia, and number of antihyper-
tensive drugs were associated with hypertension. Conclusion and Signiﬁcance. In RTR, HBPM is well accepted and better deﬁne BP
proﬁle since there is 42% discrepancy between OBPM and HBPM. Whether this discrepancy is associated with worst outcome in
the long term remains to be demonstrated.
1.Introduction
Arterial hypertension is prevalent in renal transplant recip-
ients (RTR) and is a powerful predictor of impaired graft
and patient outcome [1]. Diagnosis of arterial hypertension
has traditionally been based on measurements of blood pres-
sure (BP) in the oﬃce or clinic. However, it is known for
many years that BP, in most individuals, is higher in this
setting than in home. It is now well recognized that out-
of-oﬃce recordings of BP yield better prognostic informa-
tion than those obtained in physician’s oﬃces [2–4]. A recent
review has emphasized the advances of out-of-oﬃce recor-
dingsinpatientswithchronickidneydisease[5].Homemea-
surements can be obtained either by ambulatory BP moni-
toring or self-measurement of BP. Both these techniques
allow detecting white-coat hypertension and masked hyper-
tension. White-coat hypertension is deﬁned as well-control-
led home hypertension but poorly controlled clinic hyper-
tension. Masked hypertension is the reverse phenomenon,
poorly controlled BP at home, but normal in the clinic [6].
Furthermore, ambulatory BP monitoring gives more mea-
surements and may identify the variability of hypertension
which may be of importance [7, 8]. However, when BP is
measuredbyseveralmethods(nurse,home,ambulatory,and
doctor),ithasbeenshowedthathomemeasurementsmaybe
the most promising option, as they are the most acceptable
method to patients and were preferred to other readings in
the ambulatory monitoring. Ambulatory monitoring per-
forms less well than other methods, largely owing to dis-
comfort and disturbance of life and sleep [9, 10]. To clarify
the level of agreement among these diﬀerent blood pressure
measures, a recent study compared and showed that under
rigorously standardized conditions, clinic and home BP
c o u l db eu s e da sa na l t e r n a t i v et oa w a k eA B P[ 11]. Even2 Journal of Transplantation
thoughsomedataexistregardingambulatoryBPmonitoring
in RTR, there is only few data available concerning home BP
monitoring in this speciﬁc population [12].
2. Methods
2.1. Objectives. The aim of this study was to evaluate the
acceptability of home BP monitoring, to deﬁne the preva-
lenceofhypertensionwiththistechnique,andtodescribethe
existence of white-coat hypertension and masked hyperten-
sion in RTR. We also investigated the risk factors of patients
with speciﬁc BP proﬁle.
2.2. Participants. Between February and October 2009, we
included in this prospective observational study 87 stable
RTR. The inclusion criteria were as follow. Patients had to
have received a single renal transplant for more than one
year and to enjoy a stable renal function during the past 6
months deﬁned as less than 20% of variability of serum crea-
tinine. Immunosuppressive treatment had to be stable dur-
ing 6 months, especially regarding daily dose and blood con-
centrations of calcineurine inhibitors (CNI). The patient had
to be within targeted CNI blood concentrations, that is, cyc-
losporine concentrations 2 hours after intake (C2) between
400 and 800ng/mL; tacrolimus blood trough levels (C0)
between 4 and 12ng/mL. Antihypertensive treatments were
monitored and had to be identical for the past 6 months.
Patients were not included if systolic BP was lower than
100mmHg and higher than 190mmHg.
2.3. Description of Procedures
2.3.1. Blood Pressure Measurements. Both oﬃce and home
blood pressure was measured using a MICROLIFE BP A100
Plus device (Microlife). This automatic device generates a
digital display both of systolic blood pressure (SBP) and of
diastolic blood pressure (DBP). It has previously been vali-
dated and satisﬁed the criteria of the association for the ad-
vancement of medical instrumentation (British Hyperten-
sion Society). The device calibration was the same for home
and oﬃce. The cuﬀ was adapted to the circumference of the
arm contra lateral to the arteriovenous ﬁstula (AVF) in pa-
tientswhoseAVFwasstillfunctioning.Themachinewascali-
brated to take three measurements.
Oﬃce blood pressure was ﬁrst measured by the physician
during the clinic. The patients were then asked to have their
BP taken once again by a nurse who instructs them on how
to perform home BP measurements. BP measurements and
information was given by a unique person (CC). Both phy-
sician and nurse measurements were obtained while patients
were seated, and after they had rested for more than 5 minu-
tes.
The instructions given how to perform home blood BP
were as follows. Subjects were asked to measure their blood
pressure every morning within 1h of waking and every night
(we asked patients to wait about 10 to 12 hours between
morningandeveningmeasurements),whiletheywereseated
and after they had rested for more than 5 minutes at the time
theyhadtakentheirbloodpressuremedicationandtorecord
on a speciﬁc paper sheet the results for 4 days. We asked
patients to wait about 10 to 12 hours between morning and
evening measurements. After this period, patients returned
their device and the written results were compared to the one
recorded in the memory of the device.
2.3.2. Arterial Hypertension Deﬁnition. The home blood
pressure of an individual was deﬁned as the mean of all mea-
surements obtained for that person. The mean number of
home blood pressure measurements was 8 (at least 4 in the
morning and 4 in the evening). There was not signiﬁcant dif-
ference in measurement of HBP in morning and at evening.
Thus, we considered that the average of the both measure-
ment of HBP was valid.
We used for this study the following deﬁnition for con-
trolled and uncontrolled hypertension. For the oﬃce measu-
rements, the internationally accepted limit of 140/90mmHg
was adopted. For home BP measurement, we adopted the
internationally accepted limit of 135/85mmHg.
Patients were classiﬁed in four groups as (i) “controlled”
when their BP was below the limit for each of the methods;
(ii) “uncontrolled” when their BP was greater or equal to the
limit for each of the methods; (iii) “white coat hypertension”
when their BP was below the limit of control for HBPM and
greater than or equal to the limit for OBPM; (iv) “masked
hypertension” when their BP was below the limit for the
OBPM and greater than equal to the limit of control for the
HBPM.
2.4. Ethics. The study obtained ethics approval from the
ethics committee of the hospital named “CPP (Comit´ ed e
Protection des Personnes)”. All patients gave informed written
consent to enter the study.
2.5. Statistical Methods. Statistical analyses were performed
with the SAS JMP software version 5.0.1 for MacIntosh (SAS
Institute, Inc., Cary, NC). Characteristics of patients at the
time of the study were described using means ± standard
deviation or frequencies and compared with the chi-square
test, the Fisher’s exact test, and analysis of variance, as appro-
priate. Univariate and multivariate logistic regression were
used to determine the odds ratio and conﬁdence intervals.
Multivariate analysis was performed after adjustment for
variables identiﬁed as signiﬁcant with P<0.2i nu n i v a r i a t e
analysis.
A two-sided P value of 0.05 was considered to be statisti-
cally signiﬁcant. Furthermore, we studied the relation bet-
ween the GFR and measurement error by applying the
method as proposed by Bland and Altman [13]. We assessed
the bias as well as the 95% limits of agreement.
3. Results
3.1. Demographic Characteristics. We included 87 patients
in this study. Of note, only 81 patients were available for
analysis: 3 patients did not bring back the device; 3 patients
did not perform home BP measurements as indicated. NoJournal of Transplantation 3
Table 1: Demographic characteristics (mean ± SD, range).
Total
Age (years) 48 ±14 (24–79)
Body mass index (kg/m2) 24.8 ±4.7 (18–44)




Oﬃce systolic blood pressure (mmHg) 139 ±14 (103–181)
Oﬃce diastolic blood pressure (mmHg) 83 ±10 (55–107)
Total cholesterol (mmol/L) 4.78 ±0.97 (2.87–8)
LDL cholesterol (mmol/L) 2.49 ±0.78 (1–4.33)
HDL cholesterol (mmol/L) 1.47 ±1.09
Triglyceridemia (mmol/L) 1.68 ±0.97 (0.5–7.3)
Diabetes (%) 6
Fasting glucose level (mmol/L) 5.07 ±1.05
HbA1c (%) 5.87 ±0.09
Current smoker (%) 5.1
Creatinine (µmol/L) 137 ±39 (72–302)
Proteinuria (g/L) 0.16 ±0.27 (0–1.9)
Microalbuminuria (mg/j) 32.33 ±70.3 (0–455)




Number of antihypertensive drugs 1.5 ±1
patienthadcomplainsregardingtheacceptabilityofBPmea-
surements. Demographic characteristics of the patients are
described in Table 1. Since we included stable patients with
nolimitregardingthedelayaftertransplantation,themedian
delaywas3.08yearsrangingbetween1and31years.Atinclu-
sion, the mean serum creatinine was 137 ± 39µmol/L. The
immunosuppressive regimens were variable with 88% of pa-
tients receiving a CNI as part of the treatment. With regards
to the number of antihypertensive at the time of the study,
the mean number was 1.5 ± 1, with 16 patients receiving
no therapy, 24 patients were taking one medication, 28 pa-
tients were on two medications, 11 patients were receiving 3
medications, and 2 patients 4 medications. Among the diﬀe-
rent antihypertensive medications, 62.8% of treated patients
received beta-blockers, whereas angiotensin-converting en-
zyme inhibitors or angiotensin-2-receptor antagonists were
used in 53% and calcium channel blockers in 28.2%. New
onsetdiabetesaftertransplantation(NODAT)wasdeﬁnedby
an HbA1c value higher than 6.5% or ongoing treatment for
diabetes. In this population, 4 patients only were receiving
antidiabetic treatment consisting in insulin (n = 1) or oral
agents (n = 3).
Concerning the other cardiovascular risk factors, 56
patients (69.14%) were treated with lipid-lowering agents.
Among them, all received statins and 6 Ezetimib either alone
or in combination with statins.
3.2. Blood Pressure. We found no discrepancy between the
reported BP and reading values within the memory device.
Table 2: Number of patients with controlled and uncontrolled
home and oﬃce blood pressure (BP).
Controlled home BP Uncontrolled home BP
Controlled
oﬃce BP 21 16
Uncontrolled
oﬃce BP 16 22
We had no phantom recordings. The mean systolic and
diastolic BP values for physician were, respectively, 139 ±
14mmHg and 83 ± 10mmHg. The respective values were
134±15mmHg and 82±9mmHg for nurse BP. These mea-
surements between nurse and physicians were concordant
in 73% of patients (with 29% of hypertensive and 44% of
normotensive patients). Of note, 19% of the patients were
hypertensive with the medical doctor, although they were
only 8% with the nurse.
We then analyzed the BP values obtained with home BP
measurement. The mean systolic and diastolic home BP val-
ues were, respectively, 133±79 and 79±8mmHg. The oﬃce
BP and the home BP were correlated (r2 = 0.61; P<0.01).
However, using the deﬁnitions used (see Section 2), only
58% of the patients were classiﬁed in the same group with
bothmethods(28%controlledand30%uncontrolledhyper-
tension). These ﬁgures are summarized in Table 2.B l a n d
and Altman analysis of the data (clinical and HBP) contri-
bute to show that discrepancies are evident in the whole
range of analyzed pressures (Figure 1). Interestingly, we
found that among 37 patients with controlled oﬃce BP, 16
patients (43.2%) exhibited home high (uncontrolled) blood
pressure (masked hypertension).
3.3. Risk Factors for Blood Pressure Characteristics. We then
compared the characteristics of patient according to the def-
ined type of BP proﬁle that they presented (Table 3). Uncon-
trolled AH wasassociated with an older age, a higher value of
HbA1c, and more patients receiving antidiabetic treatment
with poor control of the diabetes mellitus. As expected, more
patients with uncontrolled and white-coat AH received anti-
hypertensive treatment (resp., 96% and 87%), even though
this diﬀerence is not statistically signiﬁcant (P = 0.06). Fur-
thermore, more than 40% of patients with uncontrolled AH
received more than 2 drugs to try to control their blood pres-
sure.
3.4. Renal Characteristics. We found no diﬀerence with
regard of the presence of hypertension (uncontrolled, white-
coat and masked) and the renal function assessed both by
serum creatinine and glomerular ﬁltration rate estimated by
the MDRD formula.
However, patients with persistent uncontrolled arterial
hypertension presented a signiﬁcantly higher excretion of
proteinuria when compared with all the other groups
(Table 4). 26/51 and 14/23 of patients with controlled
HT or noncontrolled HT, respectively, were under ARA2
or IEC (ﬁsher test, nonsigniﬁcant). Among patients with
noncontrolled HTN, frequency of proteinuria was not4 Journal of Transplantation
Table 3: Patients characteristics classiﬁed by threshold of BP normality by measurement methods (AH: arterial hypertension).
Uncontrolled AH Masked AH White-coat AH Controlled AH P
Age 55.30 ±12.65 50.87 ±15.08 50.93 ±13.66 39.81 ±10.82 0.002
Body mass index 26.61 ±0.99 24.25 ±1.18 24.13 ±1.18 24.05 ±1.03 0.23
Sex (male gender, %) 61% 50% 75% 81% 0.19
Delay 4,8 ±4.45 .12 ±6.66 .0 ±6.17 .3 ±8.30 . 6 2
HbA1c 6.34 ±0.18 5.91 ±0.22 5.61 ±0.22 5.59 ±0.65 0.03
HbA1c > 6.5% in treated patients 30% 6% 0% 5% 0.009
Total cholesterol 4.96 ±1.17 4.86 ±1.10 4.78 ±0.64 4.58 ±0.79 0.61
Triglycerides 1.64 ±0.62 1.92 ±0.97 1.94 ±1.62 1.46 ±0.63 0.39
LDL cholesterol 2.53 ±0.60 2.49 ±0.82 2.63 ±0.42 2.36 ±0.85 0.71
C2 cyclosporine 796 ±146 673 ±260 586 ±24 580 ±213 0.28
C0 tacrolimus 7.3 ±0.68 .4 ±0.77 .6 ±0.77 .7 ±0.60 . 6 9
BP treatment (Yes) 96% 80% 87% 67% 0.06
Systolic blood pressure 50
25
0


































































































































Figure 1: Bland-Altman ﬁgures of the physician and home blood pressure. Bland-Altman plots—the diﬀerence between the physician
and home blood pressure—are plotted against the physician blood pressure; therefore, a positive diﬀerence suggests an overestimation by
physician, whereas a negative diﬀerence suggests an underestimation. The solid lines represent the mean diﬀerence between physician and
home blood pressure; the dashed lines represent the 95% lines of agreement. For systolic blood pressure, the values are bias: 5.86; SD of
bias: 14.25; 95% limits of agreement (−22.08, 33.79). For diastolic blood pressure, the value is bias: 3.59; SD of bias: 11.80; 95% limits of
agreement (−19.54, 26.72).
signiﬁcantly diﬀerent in patients with and without ARA2 or
IEC treatment (0/9 versus 5/14, P>0.05, Fisher test).
4. Discussion
Cardiovascular events are the ﬁrst cause of death in RTR.
Among cardiovascular risk factors, an elevated arterial blood
pressure is recognized to be a strong predictor of graft func-
tion and patient death [1, 14–16]. Even though the preva-
lence of AH is high, the true prevalence is largely unknown
since,todate,thereisonlyfewdataregardinghomeBPwhich
has become the gold standard for BP diagnosis and follow-
up [17]. In fact Agarwal has showed that in chronic kidney
disease, blood pressures obtained at home are a stronger pre-
dictor of end-stage renal disease (ESRD) or death compared
toBPsobtainedintheclinic.SystolichomeBPisanindepen-
dent predictor of ESRD [18].
We show here that, even though mean BP is relatively
wellcontrolledinourpopulation,thereisalargediscrepancy
between home BP and oﬃce BP (in up to 42% of patients)
with both white-coat and masked AH. Since there is no good
marker to discriminate between patients with concordant BP
and the 2 previous populations, there is a need to perform
both oﬃce and home BP.
The ﬁrst question is the relative importance of home BP
compared with oﬃce BP. First, we found a very good accep-
tability and compliance for home BP in the renal transplant
population. Indeed, we found no phantom recordings. This
may be due to the fact that patients were motivated as renal
transplant recipients to assess their blood pressure with an
extensive explanation of the positive impact both by doctors
and the nurses. Stenehjem et al. have already showed that
home BP was superior to oﬃce BP in estimating BP control
in renal transplant patients with deteriorating graft function
[12]. It can also be inferred from previous studies and the
present results that the predictive power of home blood pres-
sureislargelyattributabletothefactthatithasmultiplemea-
surements [17]. One potential interest may also be to esti-
mate BP variability, which has been recently advocated to be
of utmost importance [7, 8]. It has been also suggested that,Journal of Transplantation 5
Table 4: Renal associations with hypertension.
Uncontrolled hypertension Masked hypertension White-coat hypertension Controlled hypertension P
Serum creatinine 138.3 ± 20.5 131.3 ±32.4 125.9 ±38.1 142.0 ±41.90 . 4 8
eGFR 42.8 ± 9.44 7 .4 ±15.35 3 .0 ±14.94 9 .8 ±16.30 . 1 4
Proteinuria 0.29 ±0.44 0.14 ±0.18 0.11 ±0.13 0.07 ±0.09 0.05
not only the number of measurements but also such other
factors as the lack of the white-coat eﬀect, may be associated
with the fact that predictive power of home blood pressure is
superior to that of conventional casual blood pressure.
One interesting ﬁnding in our study is that patients with
maskedBPwerealsopronetopresentmoreoftenbadcontrol
of glycemia. This could be explained by poor compliance of
both antihypertensive and diabetic drugs in the population.
One other potential advantage of home BP is the detec-
tion of both white-coat and masked hypertension. This latter
may be important since it entailed an increased risk of ESRD,
whereastheriskassociatedwithwhite-coathypertensionwas
lower [19]. This may be related to the fact that masked
hypertension by deﬁnition lasts a longer time than white-
coathypertension.Theprevalenceofmaskedhypertensionin
the general population is between 8 to 20% and can be up to
50% in treated hypertensive patients. Subjects with masked
hypertension have a higher risk of cardiovascular accidents
than normotensive subjects [19]. The variables that has been
associated with a masked hypertension in nontransplant
population are an oﬃce systolic BP higher than 130mmHg,
the male gender, patients age, more than two ongoing anti-
hypertensive and a BMI higher than 25 [20]. Apart from pa-
tient age and the number of antihypertensive drugs, we did
not ﬁnd the same risk factors possibly because of the small
sample size of our study. Of note, we found no diﬀerence
with regard to the delay after transplantation.
In our study, we found that uncontrolled BP was asso-
ciated with higher daily proteinuria excretion. Controlled
AH was associated with the lowest value of protein excretion
and both masked AH and white AH presented intermediate
value. Studies with a higher number of patients and with a
longer followup are needed to determine whether one or the
other form of AH is associated with bad prognosis.
Wealsowantedtoexplorewhetherbloodpressureassess-
mentbyanursewouldimprovetheaccuracyofthediagnosis.
Indeed, the comparison between the value of medical doctor
and nurse BP measurements show that the white-coat eﬀect
is decreased by the nurse. Even though it is imperfect, we
suggest that oﬃce BP should be better monitored by a nurse.
In conclusion, our study shows that in kidney trans-
plants,homeBPmeasurementsisacceptableandmayhelpto
b e t t e rd e ﬁ n eB Pp r o ﬁ l e .T h e r ei sat o t a lo f4 2 %d i s c r e p a n c y
between oﬃce BP and home BP. The high incidence of both
white-coat and masked hypertension suggests that the moni-
toring of RTR treated for hypertension must include home
BP self-measurement. Our study demonstrates that protein-
uria is higher with uncontrolled BP and show a tendency to
be higher in masked hypertension. Followup of a larger
population may allow demonstrating the negative eﬀect of
all proﬁles of hypertension. It also remains to be shown that
the adaptation of treatment to the results of home BP self-
measurement allows better cardiovascular prevention than
adaptation of treatment to results of measurements in the
physician’s oﬃce.
4.1. Limitations. Our study has several limitations. First, it
has been conducted only in a small pilot population. Second,
even though it is unlikely, a systematic relationship between
timing of antihypertensive drug ingestion and that of BP
measurement could explain the better values of home over
oﬃce BP measurement. Even though patients were asked to
have their BP measured at a speciﬁc time interval after drug
intake, we cannot eliminate this hypothesis since we did
not record speciﬁcally these data. Another relationship could
be proposed between the timing of blood analysis results
announcement with the stress induced and the oﬃce BP
measurement. In this regards, we could have compared the
BP at the beginning and at the end of the oﬃce visit. Be-
sides, one could argue that the BP threshold of home BP
monitoring has not been established and is perhaps diﬀerent




HBP: Home blood pressure
HBPM: Home blood pressure measurement
OBP: Oﬃce blood pressure
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